article thumbnail

Rinkelberg Capital acquires Jus-Rol from Cérélia following CMA ruling

Private Equity Insights

The CMA originally ordered Crlia to divest Jus-Rol after ruling in 2023 that the acquisition reduced competition in the UKs 100m ready-to-bake dough category. The legal battle cost the company nearly 6m. The CMA confirmed the closure of its merger investigation following the sale. Can`t stop reading?

article thumbnail

Top private equity news of the week

Private Equity Insights

The regulator, which launched the probe in December over competition concerns, confirmed on Wednesday that it will not escalate the merger to a further in-depth investigation. Several buyout firms have unknowingly backed data centres used by ByteDance, some of which may have provided a legal workaround for acquiring high-end Nvidia chips.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Judge Approves Microsoft-Activision Merger

The Motley Fool

The biggest merger in tech industry history just got the green light. On Tuesday, a federal judge in California denied the Federal Trade Commission's request for a preliminary injunction seeking to block Microsoft's monster $69 billion deal to acquire games-maker Activision Blizzard -- in effect, giving the merger the go-ahead.

article thumbnail

Pharma Giants Combine Forces to Fight New M&A Rules

The Motley Fool

With a looming overhaul of US merger-and-acquisition law set to reshape the economics of the M&A-heavy pharmaceutical industry, 31 of its biggest players -- including Merck, Amgen, Abbvie, and Gilead -- formed an alliance to fight the reforms. billion merger with Horizon Therapeutics. Meet the anti-antitrust coalition.

article thumbnail

What Will Amgen Buy Next?

The Motley Fool

Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of Horizon Therapeutics (NASDAQ: HZNP). Image source: Getty Images.

article thumbnail

Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030

The Motley Fool

The cannabis industry continues to contend with mixed legislation and legalization at the state level while a total federal ban on marijuana remains in place. The Wall Street Journal and other prominent outlets had previously reported that the company was exploring a potential merger with Boston Beer. stock exchange.

article thumbnail

5 Things to Know About Canoo Stock

The Motley Fool

Canoo was not a normal IPO Canoo came public via a merger with a special purpose acquisition company (SPAC) in late 2020. That's exactly what happened, and an increasing number of the SPAC mergers from that period are now resulting in bankruptcies. Here's five reasons you should tread carefully.